What Are the Challenges in Treating BRAF-Mutant Cancers?
Despite the initial success of BRAF inhibitors, resistance often develops over time. Tumors can acquire secondary mutations or activate alternate signaling pathways to bypass the inhibited BRAF protein. Combination therapies, including immunotherapy and other targeted agents, are being explored to overcome resistance and provide durable responses in patients.